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Review Article
Large-cell lymphocytic lymphoma
P. JACOBS, J. D. M. RICHARDS
Summary
Progress in the treatment of large-cell lymphocytic
lymphoma during the last decade has been such
that cure has replaced palliation as the objective of
treatment. In pathologically proven stage I or 11
disease appropriate radiotherapy is adequate.
It is of major importance to recognize that even in
stage III or IV disease cure is possible, and it is
therefore in the patient's best interests that initial
assessment take into account th€ morphological
and immunobiological features of the tumour as
well as other prognostic factors, and that a
chemotherapeutic regimen of established efficacy
be prescribed.
Newer challenges are a need to define optimum
chemotherapy and explore the roles of bone
marrow transplantation and immunological
manipulation of the tumour with monoclonal
antibodies.
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The clinical course in the patient with a biopsy-proven diagnosis
of lymphoma may follow one of two distinct courses. Either
progression will be slow, with survival measured in years, and in
the majority of cases the tumour cell will be a small round or
cleaved Iymphocyte and the nodal architecture will be follicular
(the indolent group), or the neoplasm will grow rapidly and will
be of high bulk, survival will be measured in months, and the
tumour cells will be large and the node diffusely effaced (the
aggressive tumours). The latter group is of interest because
during the last decade anthracycline-containing chemo-
therapeutic regimens have changed the outlook to the extent
that cure rather than palliation is the clear objective of current
management.
Survival is determined by three related variables - the
histopathological features ofrhe tumour, host prognostic factors,
and the chemotherapeutic agents used.
Histopathological features
For a long time the aggressive tumours, the dis tincti ve feature (If
which was median survival between 3 and 6 months, were called
reticulum cell sarcomas.' The name of these high-grade lesions
was changed to histiocytic lymphoma on the basis that the
microscopic fearures of the rumour cell most closely
approximated that of the normal histiocyte'" It has subsequently
become clear that while true histiocytic lymphomas may occur,
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these are a heterogeneous group of disorders) in which the
majority of the cells are transformed B lymphocytes. Consensus
has recently been . reached on how the tumours should be
classified, and it is important that each morphologically distinct
entity be identified accurately.-' Undoubtedly this is a step in the
right direction, but it will be some years before sufficient
information is available to assess the applicability of this
international grouping of the lymphomas objectively, and even
longer before its routine use becomes the basis for reporting
results in clinical trials. Nevertheless, there is no reason to persist
with older and more personal approaches except, perhaps, by
including the latter in brackets after the approved terminology.
\Vhile endorsing universal acceptance of the recently
introduced international classification, it is necessary to
recognize that it does not adequately take into account rapid
advances occurring in the understanding of lymphocyte
immunobiology. Morphologists have concentrated on
superficial similarities between rumour cells and those occurring
in normal Iymphocyte development without including
measurements of enzymes, such as terminal deoxynucleotidyl
transferase, and cell membrane surface markers in accurately
defining the neoplastic population. Even this does not go far
enough, since the presence of a particular clone identified with
an antibody provides no information about cellular function.
Such inertia, while comforting to the histologist, is hardly likely
to contribute in any major way towards understanding the
histogenesis of the lymphomas. It would therefore seem
desirable to encourage the more widespread use of an
immunohaematological approach, including examination of
suitably prepared imprints and monoclonal marker studies
carried out on cell suspensions. Failure to incorporate all of the
currently available diagnostic information severely limits the
value of any report, and may compromise the entry of patients
into clinical trials and hinder the subsequent evaluation of
response to specific chemotherapeutic regimens.
In addition to the need to 'develop a more scientific approach
to classification there is a need to see the place of staging
procedures for patients with lymphoma in clearer perspective.
There is little agreement on whether these should extend beyond
computed tomography to include surgical exploration.
Nevertheless, until this dilemma is clearly resolved students of
lymphoma need to have a clearly defined policy regarding these
important decisions. It is necessary nor only to take into account
the correct sequence of the investigations when the patient is first
seen but the increasingly important question of restaging to
confirm complete remission. Indeed, abdominal or thoracic
surgery may have its most decisive role in obtaining tissue for
histological study to reveal the subclinical persistence of occult
disease. It is on such information that the survival of an
individual may ultimately rest.
Prognostic factors
Concerning poor host prognostic factors, a number of clinical
associations are recognized.5.6 These include male sex, bone
marrow involvement, the presence of high-bulk disease
(particularly in association with gastro-intestinal tract
involvement), invasion of the central nervous system, a falling
haemoglobin concentration and a rise in lactic dehydrogenase
values. It is unacceptable for any patient v..-ith aggressive
lymphoma who is being considered for chemotherapy to be
...
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entered into a treatment programme without due consideration
being given to each of these variables. In the majority ofcases the
host factors exert their effect on survival by influencing the
number of patients w:ho achieve complete remission. For
example, involvement of the bone marrow - stage IV rather
than stage IH disease - or the presence of high-bulk disease
means that prognosis is poor, this having important bearing on
the choice of therapeutic alternatives, including bone marrow
storage for autograft 'rescue' following more aggressive
treatment during which marrow destruction becomes rate-
limiting.
Response to chemotherapy
In the final analysis it is the response to chemotherapy that has
the greatest influence on survival, and it is inexcusable to speak
of remission rates without defining their duration and the
characteristics of survival curves for patients offchemotherapy.
In pathologically defined stage I or H disease cure is possible
with appropriate extended-fieid radiotherapyY A diffuse
lymphocytic lymphoma of the large-eell variety is a high-grade
neoplasm with a multicentric site of origin. Since there is a
significant difference between radiotherapy for stage I disease
and that for stage H, an alternative approach is to use clinical
staging and chemotherapy only.9 Until such time as these issues
are resolved, there is much to recommend meticulous
pathological staging followed by radiotherapy given with
curative intent and supplemented by adjuvant chemotherapy. IQ
In stage IH and IV disease single agents may result in
dramatic response and even cure. However, this practice is
unacceptable because the complete remission rate is statistically
inferior to that in patients receiving drug regimens containing
doxorubicin (adriamycin) or one of its analogues. The single
most important advance in the treatment of these patients has
been the development of regimens incorporating an
anthracycline antibiotic, which have increased rates for both
complete remission and long disease-free survival. Furthermore,
the presence of a plateau on the survival curve ofpatients treated
in this way has led to the recognition that cure is possible in
patients with highly malignant lymphomas. II The drug regimens
have become increasingly more aggressive and complex,
.exemplified by CHOP (cyclophosphamide, hydroxydaunorubi-
cin or adriamycin, Oncovin (vincristine), and prednisone),12
BACOP (bleomycin, adriamycin, cyclophosphamide, Oncovin,
and prednisone),13 and M-BACOD (methotrexate, bleomycin,
adriamycin, cyclophosphamide, Oncovin, and
dexamethazone).14 Encouraging res ults have also been obtained
with the antimetabolite-containing regimens MEV
(methotrexate, Endoxan (cyclophosphamide), and vincristine)IS
and COMLA (cyclophosphamide, Oncovin, methotrexate,
leucovorin (folic acid) rescue, and arabinosyl cytosine).16
Against all these advances must be weighed cumulative drug
toxicity and the risk ofdeveloping secondary malignant lesions. 17
A recent studyl8 has demonstrated that in previously untreated
patients a combination of the epipodophyllotoxin VP-16-213
with doxorubicin has a similar complete remission rate to C-
MOPP (cyclophosphamide, Oncovin, procarbazine and
prednisone)19 and BACOP.13 However, while the median
survival has not been reached for these studies and the 2-year
actuarially predicted survival curves are not statistically
different, observations at 5 years show that C-MOPP and
BACOP are superior. It is not clear what the explanation for
these differences is. They may be explained by variations in
studies between institutions or a fundamental and therefore
important response to the drug regimens themselves, and a
prospective trial is now in progress to resolve this issue.
Conclusions
What should be concluded from these remarks?
A significant number of patients with stage IH and IV large-
cell lymphocytic lymphoma are curable. Since these aggressive
lymphomas are heterogeneous and results may vary between
subgroups, it is imperative that histological terminology be
standardized and that classification always include histochemical
and immunological measurements. At presentation clinical
staging may be acceptable with the advent of high-resolution
techniques, but these are less useful in confirming complete
remission, at which stage exploratory surgery with multiple-site
biopsy may well have a major role to play. Modern
chemotherapy requires at least two agents, one of which must be
an anthracycline antibiotic.
These dramatic advances clearly illustrate the vital importance
of carefully designed and meticulously executed clinical trials.
Such painstaking research is only possible wpen a
multidisciplinary approach brings together the special expertise
of haematologists, oncologists~radiotherapists, pathologists and
surgeons. It follows that with cure becoming a reality for many
patients, their best interests will be served by early referral to a
centre where such a practice is established.
And what of the future? Already there are new challenges to
face. Which histological or immllnological subsets predict
success or failure in response to current therapeutic
programmes?2Q Which of the host prognostic factors are most
important, and are they interrelated? Does central nervous
system invasion present special problems? What are the best
criteria for defining completeness of remission? At what point is
increasing chemotherapy offset by morbidity in both the short
and the long term? Will further roles for bone marrow
transplantation or immunological manipulation with monoclonal
antibodies emerge?
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